RPF

T-Mobile is Unwrapping Black Friday Deals Early. Score the Latest Tech Free!

Retrieved on: 
Tuesday, November 14, 2023
Wearables, Mobile Technology, Technology, Mobile, Wireless, Telecommunications, Hispanic, Internet, Hardware, Consumer, Consumer Electronics, Holiday, TRF, Square, Amazon Fire TV, RPF, Motorola Razr, Secure, Collection, Pixel, Mastercard, Amazon Fire, T-Mobile, Google Pixel, Samsung Galaxy Z series, Affordable Connectivity Program, Samsung Galaxy A14 5G, Business, Microsoft, Black Friday, Travel, Television, Bookkeeping, Financial services, Online shopping, Video game, Mobile phone, Metro

Free Samsung S23 FE when visiting a Metro store and bringing over your number - for a super limited time!

Key Points: 
  • Free Samsung S23 FE when visiting a Metro store and bringing over your number - for a super limited time!
  • 4 lines of Unlimited 5G for $100 and up to 4 FREE Samsung Galaxy A14 5G phones when bringing over your number and joining Metro.
  • And as an added holiday bonus, Metro is cutting activation fees this season to make switching as easy as possible.
  • Follow @TMobileNews on X, formerly known as Twitter, to stay up to date with the latest company news.

Arvinas Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, November 7, 2023
Research, Sale, Arm, Equity method, Bayer, ATM, ESMO, LRRK2, RPF, Enrollment, Greyhawk, Income tax, CTA, Prostate cancer, Exercise, Development, PROTAC, Pfizer, Clinical trial, BCL6, Neuroscience, CDK4, Breast cancer, State Administrative Expenses, ARVN, Genentech, European Society of Gynaecological Oncology, Investment, AR, Patient, Administration, Everolimus, Pharmaceutical industry, Medical imaging, Dietary supplement, Life insurance, IND, Gaius Papirius Carbo Arvina

NEW HAVEN, Conn., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Key Points: 
  • Research and Development Expenses: Research and development expenses were $85.9 million for the quarter ended September 30, 2023, as compared with $77.5 million for the quarter ended September 30, 2022.
  • General and Administrative Expenses: General and administrative expenses were $22.6 million for the quarter ended September 30, 2023, as compared with $20.0 million for the quarter ended September 30, 2022.
  • Revenues: Revenues were $34.6 million for the quarter ended September 30, 2023, as compared with $33.2 million for the quarter ended September 30, 2022.
  • Net Loss: Net loss was $64.0 million for the quarter ended September 30, 2023, as compared with $66.2 million for the quarter ended September 30, 2022.

MacroGenics Provides Update on Corporate Progress and Third Quarter 2023 Financial Results

Retrieved on: 
Monday, November 6, 2023
Research, Sale, IND, Half-life, Acute myeloid leukemia, Enoblituzumab, Bispecific monoclonal antibody, Food, Therapy, RPF, Telephone, Docetaxel, Macrogen, B7, HEAT, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Prostate cancer, Gilead Sciences, CD123, Syndrome, ADC, ID, Webcast, Cancer, Conference call, Patient, Cytokine release syndrome, Monoclonal antibody, D, Fine chemical, Pharmaceutical industry, Vaccine, Conference

ET

Key Points: 
  • ET
    ROCKVILLE, Md., Nov. 06, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended September 30, 2023.
  • Revenue: Total revenue was $10.4 million for the quarter ended September 30, 2023, compared to total revenue of $41.7 million for the quarter ended September 30, 2022.
  • R&D Expenses: Research and development expenses were $30.1 million for the quarter ended September 30, 2023, compared to $48.2 million for the quarter ended September 30, 2022.
  • SG&A Expenses: Selling, general and administrative expenses were $12.4 million for the quarter ended September 30, 2023, compared to $15.4 million for the quarter ended September 30, 2022.

Potential of Arvinas’ PROTAC® AR Degraders Reinforced by 11.1 months rPFS with Bavdegalutamide and Updated Positive Interim Data from Second Generation ARV-766 in mCRPC

Retrieved on: 
Sunday, October 22, 2023
Neoplasm, Yale School of Medicine, LBD, ESMO, Trae Elston, EDT, Vomiting, Yale school, RPF, Urology, Diarrhea, Congress, Prevalence, PFS, CEST, Prostate cancer, Nausea, PROTAC, Webcast, Interim, Oncology, ARVN, NHA, European Society for Medical Oncology, AR, Patient, Prostate, Mutation, Fatigue, Pharmaceutical industry, Flour, Medical imaging, Gaius Papirius Carbo Arvina, Medicine

NEW HAVEN, Conn., Oct. 22, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the presentation of interim data from the Company’s Phase 1/2 clinical trial for bavdegalutamide (ARV-110), a novel PROTAC® protein degrader targeting the androgen receptor (AR), in a poster session at the European Society for Medical Oncology Congress being held in Madrid from October 20 – 24, 2023. The Company will host a conference call to discuss these data and present new data from an updated analysis of its ongoing Phase 1/2 clinical trial with its second-generation PROTAC AR degrader, ARV-766, showing clinical activity extending across patients harboring tumors with AR LBD mutations and a tolerability profile that is superior to bavdegalutamide.

Key Points: 
  • AR L702H is a common AR ligand-binding domain (LBD) mutation that is not potently degraded by bavdegalutamide.
  • In patients with tumors harboring any AR LBD mutation except L702H alone, bavdegalutamide showed an rPFS of 8.2 months.
  • Our second generation PROTAC AR degrader, ARV-766, has demonstrated a broader efficacy profile and even better tolerability compared to bavdegalutamide in clinical settings.
  • ARV-766 was designed to improve upon the degradation profile of bavdegalutamide by also degrading AR L702H.

Generational Equity Advises RP Foods in its Recapitalization with Benford Capital Partners

Retrieved on: 
Monday, October 23, 2023
Professional Services, Retail, Other Retail, Supermarket, Specialty, Consulting, Food, Beverage, Partner, Ethics, CPG, History, Equity, RPF, RP, BCP, Growth, Marketing, Partnership, Mergers and acquisitions, Culture, M&A, Management, Kerosene, Palmier

Generational Equity , a leading mergers and acquisitions advisor for privately held businesses, is pleased to announce the recapitalization of its client RP Foods, LLC (“RP Foods,” “RPF” or the “Company”) with Benford Capital Partners (“Benford Capital” or “BCP”).

Key Points: 
  • Generational Equity , a leading mergers and acquisitions advisor for privately held businesses, is pleased to announce the recapitalization of its client RP Foods, LLC (“RP Foods,” “RPF” or the “Company”) with Benford Capital Partners (“Benford Capital” or “BCP”).
  • We are excited to build upon RP Foods’ strong foundation and execute our value creation plan in partnership with the management team.”
    “We are excited to partner with Benford Capital Partner in RP Foods’ next phase of growth.
  • “Generational Equity and I are so proud and honored to represent RP Foods in an M&A capacity.
  • Though we had a tremendous number of investors wanting to partner with RP Foods given our comprehensive M&A process, we knew Benford Capital was the right choice as they shared the same values, ethics, and culture as RP Foods.”

Arvinas Announces Upcoming Bavdegalutamide Poster Presentation at ESMO Congress 2023

Retrieved on: 
Sunday, October 15, 2023
Congress, ARVN, LBD, PROTAC, CEST, European Society for Medical Oncology, ESMO, Oncology, Event, Webcast, AR, EDT, RPF, Publius Cornelius Arvina, Patient, Pharmaceutical industry, HAVEN

NEW HAVEN, Conn., Oct. 15, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced it will present updated Phase 1/2 trial data for bavdegalutamide (ARV-110) at the 2023 European Society for Medical Oncology (ESMO) Annual Congress.

Key Points: 
  • NEW HAVEN, Conn., Oct. 15, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced it will present updated Phase 1/2 trial data for bavdegalutamide (ARV-110) at the 2023 European Society for Medical Oncology (ESMO) Annual Congress.
  • Bavdegalutamide is an investigational orally bioavailable PROTAC® androgen receptor (AR) degrader and is being developed as a potential treatment for men with metastatic castration-resistant prostate cancer (mCRPC).
  • This update will be presented during a poster session at the annual congress being held from October 20-24, 2023, in Madrid, Spain.
  • A replay of the webcast will be archived on the Arvinas website following the presentation.

MaxLinear and Positron Partner to Accelerate Broadband Deployment with Fiber Speeds to the Home

Retrieved on: 
Monday, October 16, 2023
Mobile, Wireless, Technology, Semiconductor, Security, Satellite, Telecommunications, Networks, Hardware, Data Management, Consumer Electronics, GAM, Digital divide, SISO, POF, QOS, MXL, Network, G.hn, Fed, CATV, MDU Wi-Fi, MIMO, Power, Quality of service, RPF, Environment, Gigabit Ethernet, Home, Wi-Fi, ITU, Internet service provider, Medical imaging, Positron, MaxLinear

The Positron GAM solutions extend fiber and fixed-wireless access Gigabit services to legacy properties over the existing coax or twisted pair wiring infrastructures.

Key Points: 
  • The Positron GAM solutions extend fiber and fixed-wireless access Gigabit services to legacy properties over the existing coax or twisted pair wiring infrastructures.
  • MaxLinear and Positron will showcase these solutions at Network X in Paris, France, October 24 – 26.
  • View the full release here: https://www.businesswire.com/news/home/20231016961564/en/
    MaxLinear and Positron Partner to Accelerate Broadband Deployment with Fiber Speeds to the Home (Graphic: Business Wire)
    The versatility of the G.hn as a Gigabit access technology standard provides subscribers with ultra-fast and reliable network connectivity.
  • “Connectivity convergence is becoming increasingly important as consumers demand reliable access at Gigabit speeds,” said Will Torgerson, Vice President, Broadband Group for MaxLinear.

Eyesafe and TÜV Rheinland Raise the Bar for Blue Light Screen Protectors

Retrieved on: 
Tuesday, September 19, 2023
Cornea, Vacuum, RPF, American National Standards Institute, International Commission on Non-Ionizing Radiation Protection, Light, SPF, ANSI, Holzmann, Certification, Blue Light, Risk, Filtration, Glass, Health, ICNIRP, Borosilicate glass, Telescopic sight, Video game

Amidst increasing scientific and medical research on blue light exposure, Eyesafe and TÜV Rheinland are releasing updated accessory requirements, targeting the light filtered between 435-440 nanometers (nm), which poses the greatest risk to retinal health.1

Key Points: 
  • Amidst increasing scientific and medical research on blue light exposure, Eyesafe and TÜV Rheinland are releasing updated accessory requirements, targeting the light filtered between 435-440 nanometers (nm), which poses the greatest risk to retinal health.1
    ZAGG is the first company to achieve Eyesafe® Accessory Requirements 2.0 and TÜV Rheinland's xx% Blue Light Reduction certification with Glass XTR3 Screen Protection.
  • MINNEAPOLIS and SHANGHAI, Sept. 19, 2023 /PRNewswire/ -- Eyesafe, a world leader in blue light mitigation technology, and TÜV Rheinland Group, a global leader in third-party testing and certification, today announced Eyesafe® Accessory Requirements 2.0 and TÜV Rheinland's xx% Blue Light Reduction certification.
  • TÜV Rheinland has issued a flyer outlining blue light reduction requirements on screen accessories.
  • ZAGG is the world's first brand to achieve Eyesafe Accessory Requirements 2.0 and TÜV Rheinland's xx% Blue Light Reduction certification.

LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone Approved in Japan for the Treatment of BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

Retrieved on: 
Thursday, August 24, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, MSD, Prednisolone, Department of Urology, University of Virginia, HRR, NHA, NR, CI, Aes, OS, Cancer, MRK, Prognosis, RPF, AstraZeneca, Merck & Co., Prednisone, Death, HIV disease progression rates, Patient, Prostate cancer, Risk, Anemia, Propel, European, Nausea, BRCA, Metastasis, FDA, ITT, NYSE, Urology, Safety, Fatigue, Pharmaceutical industry, EU, Merck

As previously reported, there was a statistically significant improvement in rPFS in the full intention-to-treat (ITT) population in the PROpel trial (n=796).

Key Points: 
  • As previously reported, there was a statistically significant improvement in rPFS in the full intention-to-treat (ITT) population in the PROpel trial (n=796).
  • In the ITT population, common adverse events (AEs) in patients who received LYNPARZA plus abi/pred were anemia (45.5%), nausea (28.1%) and fatigue (27.9%).
  • Despite various treatment options available, the prognosis for mCRPC remains poor, with limited treatment options for patients whose cancer progresses following initial treatment.
  • This combination is also approved in the U.S. for the treatment of adult patients with deleterious or suspected deleterious BRCAm mCRPC.

Celcuity Announces Plan to Conduct Phase 1b/2 Clinical Trial in Metastatic Castration Resistant Prostate Cancer

Retrieved on: 
Tuesday, August 22, 2023
Science, Disease, Q&A, RPF, Doctor of Philosophy, MD, Patient, Institut Gustave Roussy, CELC, Maghreb Virtual Science Library, Webcast, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Food, Safety, Prostate cancer, Pharmaceutical industry, Medical imaging, Medicine

MINNEAPOLIS, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, has been notified by the U.S. Food and Drug Administration (FDA) that its Investigational New Drug (IND) submission has been reviewed, and Celcuity can proceed with the clinical development of gedatolisib in combination with Nubeqa® (darolutamide), an approved androgen receptor inhibitor, for the treatment of patients with metastatic castration resistant prostate cancer (mCRPC). Celcuity’s Phase 1b/2 study (CELC-G-201) will enroll up to 54 participants with mCRPC who progressed after treatment with an androgen receptor inhibitor as first-line treatment for mCRPC. The Company anticipates initiating this Phase 1b/2 clinical trial in the first quarter of 2024.

Key Points: 
  • Celcuity’s Phase 1b/2 study (CELC-G-201) will enroll up to 54 participants with mCRPC who progressed after treatment with an androgen receptor inhibitor as first-line treatment for mCRPC.
  • The Company anticipates initiating this Phase 1b/2 clinical trial in the first quarter of 2024.
  • “We are excited to initiate the clinical development of gedatolisib in prostate cancer,” said Brian Sullivan, Chief Executive Officer and co-founder of Celcuity.
  • A replay of the webcast will be available on the “Events & Presentations” section of Celcuity’s website for a limited time following the event.